Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04485546 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
A Phase 4 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT04485546 is a Phase 4 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 37 participants.
The verdict
NCT04485546, a Phase 4 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
Interventions
- DRUG cenegermin-bkbj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04485546
The ClinicalTrials.gov registry entry for NCT04485546 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cenegermin-bkbj is the first listed.
NCT04485546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04485546 about?
NCT04485546 is a clinical study titled "Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis". This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
What is the current status of trial NCT04485546?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2020-09-09. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04485546?
The interventions under investigation include: cenegermin-bkbj (DRUG).
Who is sponsoring clinical trial NCT04485546?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.